CDC Finds Rate of New HIV Infections has Stalled
A recent report from the CDC tracking HIV trends in the U.S. from 2010 to 2016 shows that after five years of dramatic decline, the number of annual HIV infections…
340B Annual Recertification in Full Swing
This is a reminder that the 340B annual recertification period for HRSA grantees ends on February 25, 2019. Recertification must be completed through the 340B OPAIS database. The Primary Contact…
CVS Caremark Will Not Implement Planned 340B Payment Cuts
In a letter dated February 11, 2019, CVS Caremark announced that it will not implement its plan to reduce payment rates for pharmacies owned by 340B covered entities. These cuts…
CVS Caremark to Delay Reimbursement Cuts Until April 1
Earlier this week, CVS Caremark issued letters to 340B covered entity owned pharmacies announcing that it has delayed the scheduled cuts in reimbursement rates until April 1, 2019. In November…
California Medicaid Will Transition All Pharmacy Services to Fee-for-Service
On January 7, California Gov. Gavin Newsom signed an executive order instructing Medi-Cal to transition all pharmacy services for Medi-Cal managed care to fee-for-service (FFS) by January 2021. The directive…
Ryan White HIV/AIDS Providers Achieve Record Levels of Viral Suppression in 2017
In December, the Health Resources and Services Administration (HRSA) released a report affirming what RWCs know to be true – Ryan White HIV/AIDS providers are achieving record levels of viral…
Court Rules in Hospitals’ Favor in 340B OPPS Cuts Lawsuit
On December 27, 2018, the U.S. District Court for the District of Columbia struck down the portion of the 2018 OPPS rule that cut Medicare Part B drug reimbursement to…
2018 National Ryan White Conference
RWC-340B was proud to exhibit at the 2018 National Ryan White Conference on HIV Care & Treatment last week in Washington, DC. This was the first year that RWC-340B exhibited…
Proposed Rule Would Require Drug Manufacturers to Disclose Prices in TV Advertisements
On Monday, Health and Human Services Secretary Alex Azar announced a proposed rule that would require pharmaceutical manufacturers to disclose wholesale acquisition cost (“WAC”) prices in direct-to-consumer TV advertisements for…
Gilead Will Begin Marketing Lower Cost Hepatitis C Drugs in January
Gilead Sciences Inc. announced that it would begin selling generic versions of the company’s two leading treatments for hepatitis C at substantially reduced prices. The generic versions of Epclusa and…